Advertisement

Topics

Eisai Company Signs Agreement With Merck & Co. To Expand Enrollment Of Study For Halaven (Eribulin) And Pembrolizumab Combination Due To Encouraging Initial Data In Triple-Negative Breast Cancer

20:00 EDT 5 Sep 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Eisai Company Signs Agreement With Merck & Co. To Expand Enrollment Of Study For Halaven (Eribulin) And Pembrolizumab Combination Due To Encouraging Initial Data In Triple-Negative Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Eisai Company Signs Agreement With Merck & Co. To Expand Enrollment Of Study For Halaven (Eribulin) And Pembrolizumab Combination Due To Encouraging Initial Data In Triple-Negative Breast Cancer"

Quick Search
Advertisement